Shares of Aditxt Inc. traded at fractions of a penny on over-the-counter markets this week, effectively worthless, as the immunology startup's bankruptcy and liquidation process grinds forward with little prospect of meaningful recovery for common stockholders. Aditxt's Long Collapse Ends at Zero — Can Anything Salvage Value for Shareholders in Liquidation?
Shares of Aditxt Inc. now trade at effectively $0.00 on over-the-counter markets, down another 13.3% in thin, chaotic residual trading six weeks after Nasdaq pulled the plug. For investors still holding the stock, the question is no longer whether it will recover — it's whether anything at all comes back in bankruptcy.
A $35 Million Hole Made Delisting Inevitable
Nasdaq's Hearings Panel ordered Aditxt's stock suspended on June 25, 2026, citing a $(35.17 million) equity deficit, bid-price noncompliance, repeated reverse splits, and doubts over a $150 million SPAC deal.
The company had reported stockholders' equity of $(35,174,386) as of March 31, 2026 — far below Nasdaq's $2.5 million minimum — while burning roughly $5 million per quarter and executing seven reverse stock splits without sustaining compliance. In plain terms, the company owed far more than it owned and was bleeding cash with no credible plan to stop.
Nasdaq Rejected the Rescue Story
Aditxt had argued that a planned merger between its subsidiary Ignite Proteomics and a blank-check acquisition company would boost shareholder equity by about $125 million and lift the share price, but the Panel concluded the compliance plan was "not compelling or sustainable."
Regulators specifically questioned the rapid jump in Ignite's valuation from $35 million to $150 million. That skepticism matters: it signals the company's last strategic lifeline lacked credibility.
Debt Structure Ensures Common Shareholders Get Wiped Out First
Under the company's senior note agreements, a bankruptcy event triggers immediate repayment at 125% of all outstanding principal plus accrued interest.
Even before the delisting, Aditxt's market capitalization sat at just $450,000 with a current ratio of 0.31 — meaning short-term debts dwarfed liquid assets — and trailing twelve-month EBITDA was negative $19.3 million. In bankruptcy, creditors stand first in line. Common equity holders are last, and there appears to be nothing left for them.
Residual Trading Is Noise, Not a Signal
The daily percentage swings — like today's 13.3% drop — look dramatic but represent fractions of a penny moving on minuscule volume. Aditxt itself warned that delisting and capital-access loss could force it to discontinue operations entirely, "causing investors to lose their entire investment." That warning has essentially been realized. Any remaining OTC activity is speculative noise in a stock that has, for all practical purposes, ceased to exist.